EFFECT OF A STRONG INDUCER ON THE PLASMA PHARMACOKINETICS (PK) OF THE SMOOTHENED (SMO) INHIBITOR GLASDEGIB (PF-04449913).

被引：0
|
作者：
Shaik, M. [1 ]
Hee, B. [1 ]
Wei, H. [2 ]
LaBadie, R. [3 ]
机构：
[1] Pfizer Inc, San Diego, CA USA
[2] Pfizer Inc, Shanghai, Peoples R China
[3] Pfizer Inc, Groton, CT 06340 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-028
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 22 条
  • [1] Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
    Shaik, Naveed
    Hee, Brian
    Liang, Yali
    LaBadie, Robert Roland
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (07): : 895 - 902
  • [2] Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
    Shaik, M. Naveed
    LaBadie, Robert R.
    Rudin, Dan
    Levin, Wendy J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 411 - 418
  • [3] Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
    M. Naveed Shaik
    Robert R. LaBadie
    Dan Rudin
    Wendy J. Levin
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 411 - 418
  • [4] Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened
    Munchhof, Michael J.
    Li, Qifang
    Shavnya, Andrei
    Borzillo, Gary V.
    Boyden, Tracey L.
    Jones, Christopher S.
    LaGreca, Susan D.
    Martinez-Alsina, Luis
    Patel, Nandini
    Pelletier, Kathleen
    Reiter, Larry A.
    Robbins, Michael D.
    Tkalcevic, George T.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (02): : 106 - 111
  • [5] Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers
    Nagdeep Giri
    Lisa H. Lam
    Robert R. LaBadie
    Joseph F. Krzyzaniak
    Hong Jiang
    Brian Hee
    Yali Liang
    M. Naveed Shaik
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1249 - 1260
  • [6] Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS)
    Lancet, Jeffrey E.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Duong, Vu H.
    McGraw, Kathy L.
    Zhang, Ling
    Nardelli, Lisa Ann
    Ma, Zhenjun
    Reich, Richard R.
    Padron, Eric
    List, Alan F.
    BLOOD, 2016, 128 (22)
  • [7] Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies
    Minami, Yosuke
    Minami, Hironobu
    Miyamoto, Toshihiro
    Yoshimoto, Goichi
    Kobayashi, Yukio
    Munakata, Wataru
    Onishi, Yasushi
    Kobayashi, Masahiro
    Ikuta, Mari
    Chan, Geoffrey
    Woolfson, Adrian
    Ono, Chiho
    Shaik, Mohammed Naveed
    Fujii, Yosuke
    Zheng, Xianxian
    Naoe, Tomoki
    CANCER SCIENCE, 2017, 108 (08) : 1628 - 1633
  • [8] Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers
    Giri, Nagdeep
    Lam, Lisa H.
    LaBadie, Robert R.
    Krzyzaniak, Joseph F.
    Jiang, Hong
    Hee, Brian
    Liang, Yali
    Shaik, M. Naveed
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1249 - 1260
  • [9] Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration
    Lam, Justine L.
    Vaz, Alfin
    Hee, Brian
    Liang, Yali
    Yang, Xin
    Shaik, M. Naveed
    XENOBIOTICA, 2017, 47 (12) : 1064 - 1076
  • [10] Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
    Shaik, Naveed
    Hee, Brian
    Wei, Hua
    LaBadie, Robert R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 463 - 472
123